ALGS
Income statement / Annual
Last year (2023), Aligos Therapeutics, Inc.'s total revenue was $15.53 M,
an increase of 11.66% from the previous year.
In 2023, Aligos Therapeutics, Inc.'s net income was -$87.68 M.
See Aligos Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$15.53 M
|
$13.91 M
|
$4.36 M
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$3.07 M |
$3.68 M |
$104.15 M |
$3.33 M |
$2.30 M |
$1.29 M |
| Gross Profit |
$12.46 M |
$10.23 M |
-$99.79 M |
-$3.33 M |
-$2.30 M |
-$1.29 M |
| Gross Profit Ratio |
0.8 |
0.74 |
-22.89 |
0 |
0 |
0 |
| Research and Development
Expenses |
$73.04 M
|
$85.08 M
|
$104.15 M
|
$79.89 M
|
$44.04 M
|
$10.46 M
|
| General & Administrative
Expenses |
$30.62 M
|
$26.41 M
|
$28.53 M
|
$17.94 M
|
$10.01 M
|
$3.21 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$30.62 M
|
$26.41 M
|
$28.53 M
|
$17.94 M
|
$10.01 M
|
$3.21 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
-$10.55 M |
$302,000.00 |
-$435,000.00 |
| Operating Expenses |
$103.66 M |
$111.49 M |
$132.68 M |
$97.83 M |
$54.04 M |
$13.66 M |
| Cost And Expenses |
$103.66 M |
$111.49 M |
$132.68 M |
$97.83 M |
$54.04 M |
$13.66 M |
| Interest Income |
$1.24 M |
$1.64 M |
$132,000.00 |
$1.26 M |
$1.56 M |
$163,000.00 |
| Interest Expense |
$0.00 |
$1.64 M |
$132,000.00 |
$10.55 M |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$3.07 M
|
$3.68 M
|
$3.78 M
|
$3.33 M
|
$2.30 M
|
$1.29 M
|
| EBITDA |
-$83.82 M
|
-$93.91 M
|
-$124.54 M
|
-$105.06 M
|
-$49.88 M
|
-$12.37 M
|
| EBITDA Ratio |
-5.4 |
-7.02 |
-29.44 |
0 |
0 |
0 |
| Operating Income Ratio
|
-5.63
|
-7.02
|
-29.44
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$543,000.00
|
$1.64 M
|
$132,000.00
|
-$10.55 M
|
$1.86 M
|
-$272,000.00
|
| Income Before Tax |
-$86.88 M |
-$95.94 M |
-$128.19 M |
-$108.38 M |
-$52.18 M |
-$13.93 M |
| Income Before Tax Ratio
|
-5.59
|
-6.9
|
-29.41
|
0
|
0
|
0
|
| Income Tax Expense |
$795,000.00 |
$106,000.00 |
$143,000.00 |
$161,000.00 |
$85,000.00 |
-$272,000.00 |
| Net Income |
-$87.68 M |
-$96.05 M |
-$128.33 M |
-$108.54 M |
-$52.26 M |
-$13.93 M |
| Net Income Ratio |
-5.65 |
-6.91 |
-29.44 |
0 |
0 |
0 |
| EPS |
-3.52 |
-2.25 |
-3.22 |
-3.18 |
-2.38 |
-0.66 |
| EPS Diluted |
-3.52 |
-2.25 |
-3.22 |
-3.18 |
-2.38 |
-0.66 |
| Weighted Average Shares
Out |
$24.87 M
|
$42.70 M
|
$39.86 M
|
$34.18 M
|
$21.93 M
|
$21.17 M
|
| Weighted Average Shares
Out Diluted |
$24.87 M
|
$42.70 M
|
$39.86 M
|
$34.18 M
|
$21.93 M
|
$21.17 M
|
| Link |
|
|
|
|
|
|
